Thousands of people in England with a type of chronic heart failure are eligible for a new treatment option following our final draft guidance that recommends finerenone for adults with chronic heart ...

This guidance has been updated and replaced by NICE technology appraisal guidance 1007 ...

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...

This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve ...

There is a simple discount patient access scheme for nivolumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.

Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update) ...

This guidance has been updated and replaced by obesity: identification, assessment and management ...

This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is ...

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) Technology appraisal TA987 Published: 10 July 2024 Register as a stakeholder ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...